scholarly journals Injection of Botulinum Toxin a to Upper Esophageal Sphincter for Oropharyngeal Dysphagia in Two Patients with Inclusion Body Myositis

2004 ◽  
Vol 18 (6) ◽  
pp. 397-399 ◽  
Author(s):  
Louis WC Liu ◽  
Mark Tarnopolsky ◽  
David Armstrong
Keyword(s):  
Botulinum Toxin ◽  
Inclusion Body ◽  
Inclusion Body Myositis ◽  
Botulinum Toxin A ◽  
Oropharyngeal Dysphagia ◽  
Upper Esophageal Sphincter ◽  
Muscle Disease ◽  
Sphincter Pressure ◽  
Toxin A ◽  
Esophageal Sphincter

Inclusion body myositis (IBM) is a progressive degenerative skeletal muscle disease leading to weakening and atrophy of both proximal and distal muscles. Dysphagia is reported in up to 86% of IBM patients. Surgical cricopharyngeal myotomy may be effective for cricopharyngeal dysphagia and there is one published report that botulinum toxin A, injected into the cricopharyngeus muscle using a hypopharyngoscope under general anesthesia, relieved IBM-associated dysphagia. This report presents the first documentation of botulinum toxin A injection into the upper esophageal sphincter using a flexible esophagogastroduodenoscope under conscious sedation, to reduce upper esophageal sphincter pressure and successfully alleviate oropharyngeal dysphagia in two IBM patients.

Injection of botulinum toxin A for the treatment of dysfunction of the upper esophageal sphincter

2005 ◽  
Vol 26 (3) ◽  
pp. 157-162 ◽  
Author(s):  
Thomas Murry ◽  
Tamara Wasserman ◽  
Ricardo L. Carrau ◽  
Beatriz Castillo
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Upper Esophageal Sphincter ◽  
Toxin A ◽  
Esophageal Sphincter

Efficacy of Botulinum Toxin A for Treatment of Upper Esophageal Sphincter Dysfunction

2000 ◽  
Vol 110 (7) ◽  
pp. 1151-1156 ◽  
Author(s):  
Jürgen Alberty ◽  
Michael Oelerich ◽  
Karl Ludwig ◽  
Sabine Hartmann ◽  
Wolfgang Stoll
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Upper Esophageal Sphincter ◽  
Toxin A ◽  
Esophageal Sphincter

scholarly journals Balloon Dilation in Sporadic Inclusion Body Myositis Patients with Dysphagia

2013 ◽  
Vol 6 ◽  
pp. CCRep.S10200 ◽  
Author(s):  
Ken-ya Murata ◽  
Ken Kouda ◽  
Fumihiro Tajima ◽  
Tomoyoshi Kondo
Keyword(s):  
Inclusion Body ◽  
Inclusion Body Myositis ◽  
Balloon Catheter ◽  
Balloon Dilation ◽  
Ivig Therapy ◽  
Upper Esophageal Sphincter ◽  
Complementary Method ◽  
Sporadic Inclusion Body Myositis ◽  
Pharyngoesophageal Manometry ◽  
Esophageal Sphincter

Here, we describe balloon catheter dilation at the upper esophageal sphincter (UES) in three sporadic inclusion body myositis (s-IBM) patients with dysphagia. Initially, we performed IVIg therapy, and, three months later, switched to balloon dilation therapy. A 12-Fr balloon catheter was inserted from the mouth under fluoroscopy and the balloon inflated at the UES. The catheter was pulled back and re-inserted several times. We examined videofluoroscopy (VF) and pressure at the oropharynx, hypopharynx and UES using computed pharyngoesophageal manometry (CPM). Before both therapies, the VF study revealed a very small amount of barium paste passing through the UES. After balloon dilation therapy, as well as IVIg, subjective complaints of dysphagia disappeared and the VF study revealed an increased amount of barium paste passing through the UES. We conclude that balloon dilation therapy is a complementary method for conventional dysphagia therapies in s-IBM patients with dysphagia.

scholarly journals Erratum to: Botulinum toxin and rehabilitation treatment in inclusion body myositis for severe oropharyngeal dysphagia

2016 ◽  
Vol 38 (2) ◽  
pp. 377-377
Author(s):  
Chiara Di Pede ◽  
Stefano Masiero ◽  
Valentina Bonsangue ◽  
Rosario Marchese-Ragona ◽  
Alessandra Del Felice
Keyword(s):  
Botulinum Toxin ◽  
Inclusion Body ◽  
Inclusion Body Myositis ◽  
Oropharyngeal Dysphagia ◽  
Rehabilitation Treatment

Botulinum toxin and rehabilitation treatment in inclusion body myositis for severe oropharyngeal dysphagia

2016 ◽  
Vol 37 (10) ◽  
pp. 1743-1745 ◽  
Author(s):  
Chiara Di Pede ◽  
Stefano Masiero ◽  
Valentina Bonsangue ◽  
Rosario Marchese Ragona ◽  
Alessandra Del Felice
Keyword(s):  
Botulinum Toxin ◽  
Inclusion Body ◽  
Inclusion Body Myositis ◽  
Oropharyngeal Dysphagia ◽  
Rehabilitation Treatment

Botulinum toxin for the treatment of achalasia in pregnancy

2012 ◽  
Vol 1 (1-2) ◽  
Author(s):  
Heather Fels ◽  
Hindi E. Stohl ◽  
Richard H. Lee ◽  
Paola Aghajanian
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
First Trimester ◽  
Toxin A ◽  
Uncomplicated Pregnancy ◽  
Perinatal Management ◽  
First Trimester Of Pregnancy ◽  
Esophageal Sphincter ◽  
Pregnant State ◽  
In Pregnancy

AbstractThere is a paucity of data on the perinatal management of achalasia, an esophageal dysmotility disorder involving an abnormal relaxation of the lower esophageal sphincter. Botulinum toxin A is a well-described treatment for achalasia in the non-pregnant state but has been infrequently used for treatment of this condition in pregnancy. We describe a case of a successful treatment of achalasia in the first trimester of pregnancy with botulinum toxin A, and a subsequently uncomplicated pregnancy course and pregnancy outcome.

scholarly journals Achalasia in Pregnancy: Botulinum Toxin A Injection of Lower Esophageal Sphincter

2015 ◽  
Vol 2015 ◽  
pp. 1-3 ◽  
Author(s):  
Nicole Hooft ◽  
Emily S. Schmidt ◽  
Ross M. Bremner
Keyword(s):  
Botulinum Toxin ◽  
Lower Esophageal Sphincter ◽  
Botulinum Toxin A ◽  
Normal Diet ◽  
Toxin A ◽  
Esophageal Motility Disorder ◽  
Treatment Regimens ◽  
Patient Reported ◽  
Esophageal Sphincter ◽  
In Pregnancy

Background. Achalasia, a rare esophageal motility disorder that may cause malnutrition during pregnancy, can result in fetal and maternal morbidity and mortality. Many medical treatment regimens are contraindicated or not tolerated during pregnancy, and surgery is generally avoided due to potential risks to the fetus.Case Report. Severe, medically refractory achalasia in a 23-year-old pregnant woman that caused malnutrition was successfully managed by administering a botulinum toxin A injection to the lower esophageal sphincter. The injection was performed at approximately 14 weeks’ gestation and the patient reported clinically significant relief from dysphagia. She gained weight and ultimately delivered a healthy baby girl at term, but her symptoms returned a few months postpartum. She underwent a second treatment of botulinum toxin A injection, but it offered only one month of relief. Roughly eight months after delivery, the patient underwent a laparoscopic extended Heller myotomy and Dor fundoplication. The patient resumed a normal diet one week postoperatively, and her baby has had no complications.Conclusion. This is only the second reported case of botulinum toxin A injection being used to treat achalasia in pregnancy. This treatment proved to be a safe temporary alternative without the risks of surgery and anesthesia during pregnancy.

Sign in / Sign up

Export Citation Format

Share Document